Approximately 75% of all patients with colorectal carcinoma
will present at a stage when all gross carcinoma can be
surgically resected. Despite the high resectability rate, half
of all patients with colorectal adenocarcinoma die from
metastatic disease, primarily because of residual disease
that is not apparent at the time of surgery. These patients
are candidates for adjuvant local or systemic therapies.
Systmemic chemotherapy is the treatment of choice as well
as for patients with recurrent or metastatic disease.